Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Benzophenones as inhibitors of reverse transcriptase

a reverse transcriptase and benzophenone technology, applied in the direction of capsule delivery, organic active ingredients, organic chemistry, etc., can solve the problem of reducing the sensitivity of other reverse transcriptas

Inactive Publication Date: 2006-01-12
CHAN JOSEPH
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The benzophenone derivatives effectively inhibit HIV reverse transcriptase, including resistant strains, offering improved solubility and bioavailability, thus providing a more effective treatment for HIV infections and associated conditions like AIDS.

Problems solved by technology

Moreover, the mutations that appear in the reverse transcriptase enzyme frequently result in a decreased sensitivity to other reverse transcriptase inhibitors, which results in cross-resistance.
However, these compounds were primarily active against wild-type HIV-1 reverse transcriptase, rapidly induced resistant virus, and were inactive against a common resistant strain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzophenones as inhibitors of reverse transcriptase
  • Benzophenones as inhibitors of reverse transcriptase
  • Benzophenones as inhibitors of reverse transcriptase

Examples

Experimental program
Comparison scheme
Effect test

example 1

N-{4-[(acetylamino)sulfonyl]-2-methylphenyl}-2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]acetamide, Sodium Salt

[0308]

Step A:

[0309] Into a round-bottom flask were placed 2-aminotoluene-5-sulfonic acid (50.0 g, 267 mmol), and pyridine (300 mL). Acetic anhydride (38 mL, 403 mmol) was added dropwise from an addition funnel and the resulting mixture was allowed to stir for 2 h at rt. The solvents were removed under reduced pressure, leaving a brown solid. Several portions of ethyl alcohol were added to the solid and subsequently removed under reduced pressure, to afford a brown solid which was filtered and washed with several additional portions of ethyl alcohol and dried under vacuum (67.03 g, 81%). 1H NMR (DMSO-d6,) δ 2.08 (s, 3H), 2.22 (s, 3H), 7.39 (s, 2H), 7.45 (s, 1H), 8.02 (t, J=6 Hz, 2H), 8.53 (t, J=6 Hz, 1H), 8.92 (d, J=6 Hz, 2H), 9.31 (s, 1H).

Step B:

[0310] The compound from step A (67.03 g, 217 mmol) was added to a round-bottom flask containing 1N NaOH (225 mL) and t...

example 2

2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-{4-[(isobutyrylamino)sulfonyl]-2-methylphenyl}acetamide, Sodium Salt

[0323]

Step A:

[0324] Following the procedure for the synthesis of 6 and using 12 (1 g, 5.4 mmol), isobutyric acid (0.6 mL, 5.9 mL) and fuming sulfuric acid (5 mL), 15 (0.67 g, 48%) was obtained as an off-white solid.

Step B:

[0325] Following the procedure for the synthesis of 13 and using 15 (0.2 g, 0.6 mmol), 16 (0.12 g, 33%) was obtained as a white solid. 1H NMR (DMSO-d6, 300 MHz) δ 1.9 (d, 6H), 2.2 (s, 3H), 2.4 (s, 3H), 2.3-2.5 (m, 1H), 4.8 (s, 2H), 7.2 (d, 1H), 7.5 (s, 1H), 7.6-7.8 (m, 4H), 7.8-8 (m, 3H), 9.4 (s, 1H), 12 (s,.67 (s, 2H).

Step C:

[0326] Following the procedure used for the synthesis of 1 and using 16 (0.12 g, 0.2 mmol) and 1 equivalent of NaOH, 14 (0.13 g, 100%) was obtained as a white fluffy solid. 1H NMR (DMSO-d6, 300 MHz) δ 1.9 (d, 6H), 2.2 (s, 3H), 2.4 (s, 3H), 2.3-2.5 (m, 1H), 4.8 (s, 2H), 7.2 (d, 1H), 7.5 (s, 1H), 7.6-7.8 (m, 4H), 7.8-8...

example 3

2-[4-chloro-2-(3-cyano-5-methylbenzoyl)phenoxy]-N-{2-methyl-4-[(propionylamino)sulfonyl]phenyl}acetamide, Sodium Salt

[0327]

Step A:

[0328] Propionic acid (Aldrich, 1.87 mL, 25 mmol) was added dropwise to fuming sulfuric acid (5 mL) in a round bottomed flask cooled in a water bath. The solution was stirred for 1 h at rt then 4-amino-3-methylbenzenesulfonamide (5) (3.26 g, 17.4 mmol) was added in one portion. The reaction was heated to 40° C. and stirred for an additional 4 h. The syrup was poured into ice water and the pH was adjusted to 4-5 with concentrated ammonium hydroxide. The resulting suspension was stirred vigorously for 2 h. The suspension was filtered and the solid was further purified on silica gel by flash chromatography using 95:5 methylene chloride (CH2Cl2):methanol (CH3OH) as eluant to afford an orange oil (1.86 g, crude). The crude oil was triturated with diethyl ether and the resulting solid was filtered and air-dried to afford 18 as a pale yellow solid (1.46 g, 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to benzophenone compounds useful in the inhibition of HIV reverse transcriptase, particularly its resistant varieties.

Description

BACKGROUND OF THE INVENTION [0001] The human immunodeficiency virus (“HIV”) is the causative agent for acquired immunodeficiency syndrome (“AIDS”), a disease characterized by the destruction of the immune system, particularly of CD4+ T-cells, with attendant susceptibility to opportunistic infections, and its precursor AIDS-related complex (“ARC”), a syndrome characterized by symptoms such as persistent generalized lymphadenopathy, fever and weight loss. HIV is a retrovirus; the conversion of its RNA to DNA is accomplished through the action of the enzyme reverse transcriptase. Compounds that inhibit the function of reverse transcriptase inhibit replication of HIV in infected cells. Such compounds are useful in the prevention or treatment of HIV infection in humans. [0002] Non-nucleoside reverse transcriptase inhibitors (NNRTIs), in addition to the nucleoside reverse transcriptase inhibitors gained a definitive place in the treatment of HIV-1 infections. The NNRTIs interact with a sp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07C235/70C07C255/56A61K9/08C07D295/14A61K9/20A61K9/48A61K31/63A61P31/12A61P31/18C07C303/40C07C311/46C07C311/51C07C311/53C07D207/16C07D295/15
CPCC07C311/46C07C311/51C07D295/15C07D207/16C07C311/53A61P31/12A61P31/18
Inventor CHAN, JOSEPH
Owner CHAN JOSEPH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com